en.Wedoany.com Reported - Samsung Bioepis Co., Ltd. and ATLATL Innovation Centre, a global life science R&D innovation platform, recently signed a Memorandum of Understanding to jointly advance an open innovation program aimed at accelerating early-stage biotechnology development in the Asia-Pacific region. The collaboration focuses on identifying and supporting promising startups and breakthrough technologies.
Through this partnership, Samsung Bioepis will leverage ATLATL's R&D network and expertise in the Asia-Pacific biotech sector to discover and nurture early-stage innovation projects. Min Jeong Seo, Vice President and Head of the Open Innovation Group at Samsung Bioepis, stated: "External innovation is becoming increasingly critical in drug development—not only to identify and support early-stage technologies and companies, but also to build a broader innovation ecosystem. We believe that our collaboration with ATLATL, a leading biotech incubator in the Asia-Pacific region, will accelerate the translation of scientific discoveries into effective therapies for patients."
Dr. Zhu Pengcheng, Founder and CEO of ATLATL, noted: "ATLATL is dedicated to bridging early-stage science with the infrastructure and expertise needed for real-world translation. Through our integrated R&D ecosystem in the Asia-Pacific and by joining forces with Samsung Bioepis, we aspire to drive the development of high-potential technologies, bringing impactful therapeutic solutions to patients more efficiently."
As part of the collaboration, Samsung Bioepis plans to launch the 'Innovation Award,' an open innovation initiative jointly initiated with ATLATL. Selected early-stage biotech companies will have the opportunity to be hosted at ATLATL's incubation centre, leveraging its resources, infrastructure, and expertise to accelerate growth. This initiative aims to foster the biotech innovation ecosystem in the Asia-Pacific, facilitating faster patient access to cutting-edge therapies.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
